metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus sorafenib
	atezolizumab plus bevacizumab
	IMbrave-150, 2020 N. Engl. J. Med. 2020; 382:1894-1905 The Lancet Oncology J Hepatol 2022; 76:862-873-. NCT03434379	RCT	mHCC - 1st line (L1)	atezolizumab-bevacizumab	sorafenib	patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment	336 / 165	some concern	conclusif	demonstrated 42 % decrease in deaths (OS) (PE) demonstrated 41 % decrease in progression or deaths (PFS) (PE) demonstrated 1.8-fold increase in objective responses (ORR) (PE)
	nivolumab alone
	CheckMate 459, 2019 Annals of Oncology 2019 Lancet Oncol 2022 Jan;23(1):77-90. NCT02576509	RCT	mHCC - 1st line (L1)	nivolumab	sorafenib	first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) / patients (at least 18yr) with hiistologically confirmed advanced hepatocellular carcinoma ot eligible for, or whose disease had progressed after, surgical or locoregional therapies	371 / 372	some concern	suggested	inconclusive 15 % decrease in deaths (OS) (PE)